Effects of fenofibrate on lipid parameters in obese rhesus monkeys

Effects of fenofibrate on lipid parameters in obese rhesus monkeys

Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia. The fibrates were developed primarily on the basis of their cholesterol and triglyceride lowering in rodents. Fibrates have historically been ineffective at lo...

Full description

Bibliographic Details
Main Authors:	Deborah A. Winegar, Peter J. Brown, William O. Wilkison, Michael C. Lewis, Ronda J. Ott, W.Q. Tong, H. Roger Brown, Jurgen M. Lehmann, Steven A. Kliewer, Kelli D. Plunket, James M. Way, Noni L. Bodkin, Barbara C. Hansen
Format:	Article
Language:	English
Published:	Elsevier 2001-10-01
Series:	Journal of Lipid Research
Subjects:	fibrate PPARα triglyceride-lowering HDL-C apolipoprotein C-III
Online Access:	http://www.sciencedirect.com/science/article/pii/S0022227520322070

Similar Items

LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
by: Ariel Brautbar, et al.
Published: (2012-03-01)

Fibrane the reduced derivative of fenofibrate
by: Amanda E. Kotheimer, et al.
Published: (2020-01-01)

Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet
by: Ying Zhang, et al.
Published: (2022-09-01)

Fenofibrate Decreases Ethanol-Induced Neuroinflammation and Oxidative Stress and Reduces Alcohol Relapse in Rats by a PPAR-α-Dependent Mechanism
by: Cristina Ibáñez, et al.
Published: (2023-09-01)

Effect of Lipids on Diabetic Retinopathy in a Large Cohort of Diabetic Patients after 10 Years of Follow-Up
by: Pedro Romero-Aroca, et al.
Published: (2023-10-01)

The Differential Effects of HDL Subpopulations on Lipoprotein Lipase (LPL)-Mediated VLDL Catabolism
by: Ewa Wieczorek, et al.
Published: (2021-12-01)

Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities
by: Watts Gerald F
Published: (2001-05-01)

Plasma Apolipoprotein Concentrations Are Highly Altered in Severe Intensive Care Unit COVID-19 Patients: Preliminary Results from the LIPICOR Cohort Study
by: Floran Begue, et al.
Published: (2023-02-01)

Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats
by: Ana Soria, et al.
Published: (2002-01-01)

Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome
by: Marat V. Ezhov, et al.
Published: (2023-10-01)

Design and synthesis of guaiacol-based fibrate derivatives with potential hypolipidemic and liver protective actions
by: Yan Zhang, et al.
Published: (2024-01-01)

The Small Molecule PPARγ Agonist GL516 Induces Feeding-Stimulatory Effects in Hypothalamus Cells Hypo-E22 and Isolated Hypothalami
by: Annalisa Chiavaroli, et al.
Published: (2022-07-01)

Effect of <em>CYP3A4</em>*22 and <em>PPAR-α</em> Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention
by: Thomas O. Bergmeijer, et al.
Published: (2020-09-01)

Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
by: Claudia Sagheddu, et al.
Published: (2021-10-01)

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
by: Francesca Colapietro, et al.
Published: (2023-01-01)

Induction of Tissue Factor Expression in Endothelial Cells by Basic Fibroblast Growth Factor and its Modulation by Fenofibric acid
by: Hamada Junichi, et al.
Published: (2003-10-01)

Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate
by: Ananthi Rajamoorthi, et al.
Published: (2017-11-01)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
by: Tarantino N, et al.
Published: (2017-02-01)

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing
by: Alpo Vuorio, et al.
Published: (2022-12-01)

Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI
by: Thomas J.F. Nieland, et al.
Published: (2007-08-01)

The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptions
by: Furberg Curt D
Published: (2001-05-01)

Impact of concomitant fibrates on immunotherapy outcomes for advanced non‐small cell lung cancer
by: William A. Stokes, et al.
Published: (2023-01-01)

Fibrate-based N-acylsulphonamides targeting carbonic anhydrases: synthesis, biochemical evaluation, and docking studies
by: Alessandra Ammazzalorso, et al.
Published: (2019-01-01)

Fenofibrate Administration Reduces Alcohol and Saccharin Intake in Rats: Possible Effects at Peripheral and Central Levels
by: Mario Rivera-Meza, et al.
Published: (2017-07-01)

Lipoprotein Glomerulopathy, First Case Report from Canada
by: Ting JA, et al.
Published: (2022-06-01)

Apolipoprotein B/A1 Ratio as a Diagnostic Alternative to Triglycerides and HDL-Cholesterol for the Prediction of Metabolic Syndrome among Hypertensives in Kazakhstan
by: Alma Nurtazina, et al.
Published: (2020-07-01)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
by: Farnier Michel, et al.
Published: (2011-11-01)

Fenofibrate (a PPAR-α Agonist) Administered During Ethanol Withdrawal Reverts Ethanol-Induced Astrogliosis and Restores the Levels of Glutamate Transporter in Ethanol-Administered Adolescent Rats
by: Francisca Villavicencio-Tejo, et al.
Published: (2021-04-01)

Evidence for differential effects of apoE3 and apoE4 on HDL metabolism
by: Paul C.R. Hopkins, et al.
Published: (2002-11-01)

Which one of LDL-C /HDL-C ratio and non-HDL-C can better predict the severity of coronary artery disease in STEMI patients
by: Po Gao, et al.
Published: (2022-07-01)

Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
by: Caroline C. van der Hoogt, et al.
Published: (2007-08-01)

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis
by: Floreani A
Published: (2020-12-01)

The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models
by: Scott P. Davies, et al.
Published: (2021-08-01)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
by: Irina N. Gorshkova, et al.
Published: (2023-02-01)

Novel Size‐Based High‐Density Lipoprotein Subspecies and Incident Vascular Events
by: Austin Deets, et al.
Published: (2023-11-01)

Circulating HDL and Non-HDL Associated Apolipoproteins and Breast Cancer Severity
by: Christine Bobin-Dubigeon, et al.
Published: (2022-02-01)

Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?
by: Eric J. Niesor
Published: (2015-01-01)

THE EFFECTS OF SIMVASTATIN, ROSUVASTATIN, AND FENOFIBRATE ON THE BODY WEIGHT AND LIPID PROFILES OF FEMALE RATS TREATED WITH ORAL CONTRACEPTIVES AND A HIGH-FAT DIET
by: Dwi Anggara Putri, et al.
Published: (2022-09-01)

VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate
by: Michel Farnier, et al.
Published: (2008-12-01)

Reconfiguring Nature’s Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents
by: Skylar T. Chuang, et al.
Published: (2020-05-01)